Bob Holland has joined Oxford Gene Technology as its chief medical officer.
Holland previously served as vice president and head of AstraZeneca's Personalized Healthcare and Biomarkers division.
In his new role at OGT, Holland will lead clinical affairs across OGT's business areas. He will work with the UK company's R&D and commercial teams to develop clinical development programs that will expand its next-generation sequencing and microarray cancer profiling solutions. Holland will also work with OGT's biomarker programs for prostate and colorectal cancers, OGT said.